Cytokinetics EVP R&D Malik Fady Ibraham disposes of 3,500 common shares for $264,110
Reuters2026/09/08 20:39- Fady Ibraham Malik, EVP Research & Development at Cytokinetics, sold 3,500 common shares on Sep. 8, 2026 at USD 75.46.
- Sale followed the exercise of 3,500 non-qualified stock options at USD 7.8 per share.
- Direct common stock holdings fell to 153,902 shares.
- Non-qualified stock options held declined to 26,886, with an exercise price of USD 7.8.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Sasol agrees to sell Nitrates business to Enaex Africa, keeps 23% stake
The United States implements import bans on some Canadian products. Which US stocks are affected?
The United States has imposed tariffs on certain Canadian products, making these U.S. stocks worth watching.
Jing Rui Wang Pu (JRWP.US) makes another attempt to list on Nasdaq, raising the fundraising amount significantly to $31 million.
JRWP.US resubmitted its initial public offering (IPO) application to the U.S. Securities and Exchange Commission (SEC) on Tuesday.
Asiamet Resources LTIP Tranche 1 vests, converts 79.85 million performance rights into shares
Crypto prices
More
